Onpattro (Patisiran)

Overview
Onpattro is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with nerve damage resulting from hereditary transthyretin-mediated (hATTR) amyloidosis. Onpattro is also… read more

Vyndamax (Tafamidis)

Overview
Vyndamax is approved by the U.S. Food and Drug Administration (FDA) for the treatment of cardiomyopathy (heart muscle disease) caused by wild-type or hereditary transthyretin-mediated amyloidosis. This treatment…

Vyndaqel (Tafamidis meglumine)

The Vyndaqel brand name has been discontinued in the U.S. Other brand name or generic alternatives may be available.

Overview

Vyndaqel is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to…

Wainua (Eplontersen)

Overview
Wainua is approved by the U.S. Food and Drug Administration (FDA) for the treatment of polyneuropathy (nerve damage) caused by hereditary transthyretin-mediated amyloidosis in adults. This medication is…